SCHEMBL968255

SCHEMBL968255

Sc1nnc(-c2cnc3ccccc3c2)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 3/20 0.49
PDGFRA P16234 3/20 0.49
PIM1 P11309 3/20 0.46
PIM3 Q86V86 3/20 0.46
PIM2 Q9P1W9 2/20 0.46
CYP2A6 P11509 1/20 0.46
BIRC5 O15392 1/20 0.45
PIK3CD O00329 2/20 0.44
PIK3CA P42336 2/20 0.44
NISCH Q9Y2I1 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
CYP1A2 P05177 1/20 0.42
MGAM O43451 1/20 0.41
MAP4K4 O95819 1/20 0.40
CSNK1G2 P78368 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL969364 0.77 PTPN11 (0.47) CYP1A2NPC1MAPTRAB9AALDH1A1
SCHEMBL32667946 0.75 PDGFRB (0.77) PDGFRBPDGFRACYP2A6BIRC5PIK3CD
SCHEMBL2772360 0.75 PDGFRB (0.77) PDGFRBPDGFRACYP2A6BIRC5PIK3CD
SCHEMBL27631123 0.74 PDGFRB (0.51) PDGFRBPDGFRAPIM1PIM3PIM2
SCHEMBL29890141 0.73 CYP1A2 (0.43) CYP1A2NPC1MAPTRAB9AALDH1A1
SCHEMBL27631124 0.73 PDGFRB (0.58) PDGFRBPDGFRAPIM1PIM3PIM2
SCHEMBL969040 0.72 ALDH1A1 (0.52) CA1CA2MGAMNPC1RAB9A
SCHEMBL3063161 0.71 PDGFRB (0.59) PDGFRBPDGFRAPIM1CYP2A6BIRC5
SCHEMBL708999 0.70 PDGFRB (0.75) PDGFRBPDGFRACYP2A6BIRC5PIK3CD
SCHEMBL27724702 0.70 BIRC5 (0.54) PDGFRBPDGFRAPIM1PIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7871982-B2 Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient MEIJI SEIKA KAISHA, LTD. (JP) 2011-01-18 US disclosed
US-20090156512-A1 potent activity against resistant pneumococci MEIJI SEIKA KAISHA, LTD. (JP) 2009-06-18 US disclosed
EP-1970377-A1 LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD. (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156512-A1 potent activity against resistant pneumococci H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 PDGFRB 4843/4885PDGFRA 4827/4885PIM1 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.